Shares of Sorrento Therpt (SRNE) are trading 5% higher at a price of $2.585 at the time of this writing.

Sorrento Therpt has been trading between a 52-week high of $9.63 and a 52-week low of $1.15. The stock has a market cap of $1.01 Billion.

Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies ('G-MAB™library'), clinical stage immuno-cellular therapies ('CAR-T', 'DAR-T'), antibody-drug conjugates ('ADCs'), and clinical stage oncolytic virus ('Seprehvir®'). Sorrento is also developing potential coronavirus antiviral therapies and vaccines, including COVIDTRAP™, ACE-MAB™, COVI-MAB™, COVI-GUARD™, COVI-SHIELD™and COVI-CELL™.

Sorrento Therapeutics Inc. (NASDAQ: SRNE) Could See A Rise In Prices Shortly.
Marketing Sentinel 08-01-22

Increasing unusual put option volume: TIP CLVS TEN TSM MXEA DM SRNE
Investing.com 08-01-22

10 Stocks to Sell Before They Die
InvestorPlace 07-29-22

FDA Clears Sorrento''s STI-1558 Phase 1 Study To Treat COVID-19 Infection
Benzinga 07-20-22

SRNE stock gains as FDA clears Phase 1 trial for COVID-19 therapeutic (NASDAQ:SRNE)
Seeking Alpha 07-19-22


As you can imagine, the internet had a few things to say about the price move. Here's a few choice comments from the Reddit Traderverse™:

atoastedcucumber - 2 upvotes - source
SRNE and RKLB. My literal only plays.

BeTheBeach - 1 upvotes - source
SRNE = the NKLA of biotech.